Sastre, J., Pallard, F., Via, J
Segn los datos de los ensayos clnicos y la informacin de prescripcin de la FDA, estos incluyen nuseas (aproximadamente 20-33% de pacientes), diarrea (18-23%), estreimiento (11-17%), vmitos (9-12%) y dolor abdominal
The clients I have seen who maintained their weight loss most successfully after discontinuing GLP-1 therapy were uniformly the ones who had established a strength training habit during treatment
Oral kullanlrlar
however, the process is clear if you know what to do
Some patients report dramatic appetite suppression, whilst others experience more modest effects